In this episode of the Active Ingredients podcast, host Thomas Dove interviews Gaurav Jain, Chief Commercial Officer (CCO) at Modavar Pharmaceuticals LLC.

Gaurav Jain is a globally experienced commercial leader with over 22 years in the pharmaceutical industry. He has led business development and mergers and acquisitions (M&A) across branded generics, orphan drugs, and multinational companies in markets spanning Asia, the United States, and beyond.

In this conversation, Gaurav explains how he entered the industry by chance and built his career by setting clear goals, staying adaptable, and taking on challenges beyond his experience. He also shares how pharma deal structures have shifted away from large upfront payments toward models in which both partners share risk based on a product's performance. He also discusses how senior leaders can protect their organisations from the disruption caused by rising trade barriers and global supply chain instability.

 Key Takeaways

• Learn why clear objective setting forms the foundation of effective leadership in pharmaceutical organisations, and how defining deliverables from day one gives teams direction and prevents wasted effort.
• Discover how Gaurav Jain's career path from banking into branded generics and M&A shows that subject matter expertise matters less than the ability to work with experts and ask the right questions.
• Understand how to build high-performing commercial teams by hiring for motivation and mindset rather than industry knowledge alone, and why open dialogue leads to stronger business outcomes.
• Explore how performance-based deal structures have replaced front-loaded payments in pharmaceutical partnerships, and why shared risk now underpins long-term commercial relationships of all sizes.
• Identify the steps senior leaders should take to protect their organisations from rising global trade barriers, including diversifying supply chains, monitoring P&L exposure, and engaging proactively with policymakers.

Snippets

•  ”You don't need to be an expert in every space. What you need to know is how experts perform in their own space, and how to work with the experts to learn enough to work along with the greater organisation.”

• ”Even after you close the deal, it's not the end. It's kind of a beginning of another major set of challenges… You might have a great idea, but if you don't really follow up on those ideas during integration, you kind of lose value.”

• ”A lot of times I've seen industry professionals look at AI as something that can just shorten the amount of thinking they need to do. AI is not a substitute to strategy, to vision, to thinking, to a challenge.”

Timestamps & Topics

The following timestamps are approximations:

• [00:29] Key Ingredients: Objective setting, adaptability and strategic planning
• [00:31] Career Path: From banking into the pharmaceutical industry
• [00:47] Deal Making: What makes M&A a genuine breakthrough for an organisation
• [00:54] Partnership Evolution: How deal structures have shifted to performance-based models
• [00:59] Trade Barriers: Navigating geopolitical disruption and supply chain risk
• [01:07] Future of Leadership: AI, data and the next generation of life sciences leaders

Resources

• Follow Gaurav Jain on LinkedIn: https://www.linkedin.com/in/gaurav-jain-032b9417/

• ResourcesFollow Thomas Dove on LinkedIn: https://www.linkedin.com/in/lifesciencesexecutivesearch/

Don't Miss an Episode

Sign up to the Active Ingredients podcast at ⁠⁠⁠⁠⁠⁠www.activeingredients.fraserdove.com⁠⁠⁠⁠⁠⁠.

Remember to tune into our next episode for more inspiring insights. You can also subscribe to the Active Ingredients podcast on ⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠Amazon⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠ and other leading podcast platforms.

Loved this episode?

Share it with your friends, family, or your peers!